<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(2)</volume><submitter>Fonseca A</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Due to advances in screening and treatment of lung cancer, there has been increased interest in long-term lung cancer survivors (LTLCS). The aim of this study was to evaluate the prevalence of LTLCS, their characteristics and patient-reported outcomes (PROs) of LTLCS.&lt;h4>Methods&lt;/h4>Cross-sectional study that included patients diagnosed with primary lung cancer between Jan 2012 and Dec 2016 whose overall survival (OS) was greater than 5 years. A self-administered questionnaire was applied, including European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30), Patient Health Questionnaire-4 (PHQ-4) and two open questions regarding quality of life (QoL) and suggestions for improvements. Factors potentially related to QoL were analysed.&lt;h4>Results&lt;/h4>Of 767 lung cancer patients, 158 (20.6%) were LTLCS and LTLCS' proportion increased yearly. Most patients were male (70.9%) with median age of 65 [interquartile range (IQR), 56-71] years. Fifty-seven percent had adenocarcinoma, 66.2% were diagnosed at early stages but 8.9% were at stage IV. During follow-up, 77.1% quitted smoking, 31.8% had disease progression/relapse and 15.2% developed other tumours. Of all living LTLCS, 100 (85%) patients answered the PROs questionnaire. The median Global Health score was 66.67 (IQR, 50-83), social functioning had the best score and emotional functioning the worst. Pain and fatigue were the symptoms with the worst impact on QoL. PHQ-4 identified mental distress in 36% and patients with a lower QoL were more likely to present anxiety (35.3% &lt;i>vs.&lt;/i> 9.4%, P=0.007) or depression (27.9% &lt;i>vs.&lt;/i> 3%, P=0.006). In the open questions, patients reported pain (17%), lack of familiar/financial support (16%), dyspnoea (14%), depression (8%), concern for the future (8%) and limitations performing daily activities (8%) as the aspects with most impact in QoL. The most suggested measures were improvement of care provided by health institutions (25%) and better social support (16%).&lt;h4>Conclusions&lt;/h4>Prevalence of LTLCS is increasing and survivors may experience a high prevalence of anxiety and depression as well as a high disease burden affecting QoL. Therefore, it's important to provide multidisciplinary continuous patient-centred care and a careful follow-up for all lung cancer patients, including LTLCS.</pubmed_abstract><journal>Journal of thoracic disease</journal><pagination>1087-1096</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10944758</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Characteristics and patient-reported outcomes of long-term lung cancer survivors.</pubmed_title><pmcid>PMC10944758</pmcid><pubmed_authors>Antunes M</pubmed_authors><pubmed_authors>Firmino-Machado J</pubmed_authors><pubmed_authors>Fonseca A</pubmed_authors><pubmed_authors>Barroso A</pubmed_authors><pubmed_authors>Dias M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Characteristics and patient-reported outcomes of long-term lung cancer survivors.</name><description>&lt;h4>Background&lt;/h4>Due to advances in screening and treatment of lung cancer, there has been increased interest in long-term lung cancer survivors (LTLCS). The aim of this study was to evaluate the prevalence of LTLCS, their characteristics and patient-reported outcomes (PROs) of LTLCS.&lt;h4>Methods&lt;/h4>Cross-sectional study that included patients diagnosed with primary lung cancer between Jan 2012 and Dec 2016 whose overall survival (OS) was greater than 5 years. A self-administered questionnaire was applied, including European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30), Patient Health Questionnaire-4 (PHQ-4) and two open questions regarding quality of life (QoL) and suggestions for improvements. Factors potentially related to QoL were analysed.&lt;h4>Results&lt;/h4>Of 767 lung cancer patients, 158 (20.6%) were LTLCS and LTLCS' proportion increased yearly. Most patients were male (70.9%) with median age of 65 [interquartile range (IQR), 56-71] years. Fifty-seven percent had adenocarcinoma, 66.2% were diagnosed at early stages but 8.9% were at stage IV. During follow-up, 77.1% quitted smoking, 31.8% had disease progression/relapse and 15.2% developed other tumours. Of all living LTLCS, 100 (85%) patients answered the PROs questionnaire. The median Global Health score was 66.67 (IQR, 50-83), social functioning had the best score and emotional functioning the worst. Pain and fatigue were the symptoms with the worst impact on QoL. PHQ-4 identified mental distress in 36% and patients with a lower QoL were more likely to present anxiety (35.3% &lt;i>vs.&lt;/i> 9.4%, P=0.007) or depression (27.9% &lt;i>vs.&lt;/i> 3%, P=0.006). In the open questions, patients reported pain (17%), lack of familiar/financial support (16%), dyspnoea (14%), depression (8%), concern for the future (8%) and limitations performing daily activities (8%) as the aspects with most impact in QoL. The most suggested measures were improvement of care provided by health institutions (25%) and better social support (16%).&lt;h4>Conclusions&lt;/h4>Prevalence of LTLCS is increasing and survivors may experience a high prevalence of anxiety and depression as well as a high disease burden affecting QoL. Therefore, it's important to provide multidisciplinary continuous patient-centred care and a careful follow-up for all lung cancer patients, including LTLCS.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2026-06-23T03:17:38.073Z</modification><creation>2025-04-06T13:55:34.052Z</creation></dates><accession>S-EPMC10944758</accession><cross_references><pubmed>38505031</pubmed><doi>10.21037/jtd-23-1494</doi></cross_references></HashMap>